Viewing
News|Articles|November 18, 2026

MacuMira receives CE Mark for microcurrent treatment of dry AMD

The non-invasive device, already available in Canada, Australia, and New Zealand, delivers low-level microcurrent through closed eyelids in 32-minute in-clinic sessions.

MacuMira Medical Devices has received CE Mark certification for its retinal microcurrent stimulation device for dry age-related macular degeneration (AMD), opening a pathway into Europe for a treatment already offered to patients in Canada, Australia, and New Zealand.1

The device has been certified as a Class IIa medical device under the EU Medical Device Regulation (MDR 2017/745). Matt Van de Ven, the company’s CEO, called the certification ‘a significant milestone for MacuMira’ and an important step towards broadening access to the technology, noting that patients with dry AMD have historically had few options.1

A large and underserved population

AMD remains a leading cause of vision loss in adults older than 50 years. Global prevalence was estimated at 196 million people in 2020 and is projected to reach 288 million by 2040,2 with approximately 67 million people affected in Europe alone.3

Most patients have the dry form of the disease. Although the complement inhibitors pegcetacoplan and avacincaptad pegol have brought the first approved therapies to geographic atrophy (GA), the late stage of dry AMD, retina specialists continue to weigh when and in whom to initiate treatment.10,11 For patients with earlier-stage dry disease, management has largely consisted of nutritional supplementation and monitoring.

How the treatment works

In each 32-minute session, a trained technician delivers low-level microcurrent stimulation through the patient’s closed eyelids. Treatment begins with a loading phase of successive sessions, followed by periodic maintenance treatments.1

The company believes the stimulation activates cellular metabolic processes in the photoreceptors and retinal pigment epithelium. When the device launched in Canada, MacuMira described the mechanism as improving mitochondrial function, reducing inflammation, and increasing adenosine triphosphate (ATP) production.5 Notably, the company positions the treatment as a means of improving vision rather than solely slowing disease progression.1

The clinical evidence

The primary evidence base is a randomised, sham-controlled trial published in 2023 in the International Journal of Retina and Vitreous.4 The study enrolled 43 patients in the treatment arm and 19 in the sham arm. Mean Early Treatment Diabetic Retinopathy Study (ETDRS) letter scores in the treatment group rose from 19.6 at baseline to 27.8 at 30 weeks, while scores in the sham group declined from 24.2 to 22.1. According to the company, this corresponds to a mean gain of 10.4 letters over sham, with contrast sensitivity improving by 0.25 log units more than in the sham group.1,4

MacuMira also cited an internal, unpublished retrospective analysis of 251 patients treated across 24 clinics, encompassing more than 1,700 treatments. Patients gained a mean of 6.4 letters within the first 2 weeks, and visual acuity remained within 2.4 letters of that peak through 15 months, according to the company. MacuMira reports that the treatment has been well tolerated.1

‘Patients with atrophic macular degeneration need options to maintain and preserve vision both short- and long-term,’ said Marc de Smet, MD, CM, PhD, a retinal surgeon and director of MicroInvasive Ocular Surgery in Lausanne, Switzerland. He described the approach as novel and said a priority is identifying which patients are most likely to benefit.1

Questions about the evidence

The European certification arrives against a backdrop of professional caution in the company’s home market. In a December 2024 joint position statement, the Canadian Ophthalmological Society and the Canadian Retina Society concluded that long-term evidence was insufficient to confirm the treatment’s safety or efficacy.6

The societies noted that the pivotal data came from a single-site, company-funded study with a 30-week follow-up and a sample too small to generalise to a broader population. While they acknowledged that improvements in visual acuity and contrast sensitivity were observed without evidence of harm, they did not support public funding or fee-for-service billing for the treatment and called for larger, more diverse, multicentre randomised controlled trials with longer follow-up.6

It is also worth noting that CE marking of a medical device under the MDR reflects a notified body’s conformity assessment of safety and performance, a different evidentiary pathway from regulatory approval of a pharmaceutical.

A growing field of energy-based therapies

MacuMira is one of several companies pursuing device-based approaches to dry AMD. At the Retina Society 2026 meeting, investigators presented results from the randomised, sham-controlled i-SIGHT pilot study of transpalpebral microcurrent stimulation with a different device, which reported reductions in ellipsoid zone defects and improved photoreceptor function on multifocal electroretinography through 12 months. The authors characterised the findings as preliminary proof of concept requiring confirmation in larger studies.7

Photobiomodulation offers another energy-based approach. The Valeda Light Delivery System received FDA De Novo marketing authorisation in November 2024,8 becoming the first CE-marked and FDA-cleared ophthalmic photobiomodulation platform for dry AMD; the system is now commercialised by Alcon.9

Looking ahead

With CE marking in hand, MacuMira can pursue commercialisation across EU member states, although availability will depend on country-specific requirements.1 For European retina specialists, the arrival of the device is likely to renew the same questions raised in Canada: how durable the visual gains are, which patients are the best candidates and whether independent, multicentre data will confirm the early results.

References
  1. MacuMira receives CE Mark for its microcurrent treatment for dry AMD. News release. MacuMira Medical Devices Inc. November 16, 2026. Accessed November 18, 2026. https://www.globenewswire.com/news-release/2026/11/16/3403489/0/en/macumira-receives-ce-mark-for-its-microcurrent-treatment-for-dry-amd.html
  2. Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106-e116. doi:10.1016/S2214-109X(13)70145-1
  3. Li JQ, Welchowski T, Schmid M, Mauschitz MM, Holz FG, Finger RP. Prevalence and incidence of age-related macular degeneration in Europe: a systematic review and meta-analysis. Br J Ophthalmol. 2020;104(8):1077-1084. doi:10.1136/bjophthalmol-2019-314422
  4. Parkinson KM, Sayre EC, Tobe SW. Evaluation of visual acuity in dry AMD patients after microcurrent electrical stimulation. Int J Retina Vitreous. 2023;9:36.
  5. Filkins K. MacuMira launches first Health Canada-approved device for AMD treatment. Ophthalmology Times. Published September 26, 2025. Accessed November 18, 2026. https://www.ophthalmologytimes.com/view/macumira-launches-first-health-canada-approved-device-for-amd-treatment
  6. Canadian Ophthalmological Society, Canadian Retina Society. Joint position statement on the use of a patented microcurrent electrical stimulation technology for the treatment of dry AMD. December 6, 2024. Accessed November 18, 2026. https://cosprc.ca
  7. Charters L. Retina Society 2026: Non-invasive electrical stimulation therapy for intermediate dry AMD: improved retinal health and visual acuity. Ophthalmology Times. Published September 26, 2026. Accessed November 18, 2026. https://www.ophthalmologytimes.com/view/retina-society-2026-non-invasive-electrical-stimulation-therapy-intermediate-dry-amd-improved-retinal-health-and-visual-acuity
  8. FDA authorizes marketing of Valeda Light Delivery System for treatment of patients with dry AMD. Ophthalmology Times. Published November 12, 2024. Accessed November 18, 2026. https://www.ophthalmologytimes.com/view/fda-authorizes-marketing-of-valeda-light-delivery-system-for-treatment-of-patients-with-dry-amd
  9. The Retina TL;DR with Dr. Weng: Unpacking photobiomodulation for dry AMD with Drs. Do, Lad, and Munk. Ophthalmology Times. Published April 16, 2026. Accessed November 18, 2026. https://www.ophthalmologytimes.com/view/the-retina-tl-dr-with-dr-weng-unpacking-photobiomodulation-for-dry-amd
  10. Hoffman M. Navigating treatment decisions in geographic atrophy: what three complex cases reveal. Ophthalmology Times. Published July 31, 2026. Accessed November 18, 2026. https://www.ophthalmologytimes.com/view/navigating-treatment-decisions-in-geographic-atrophy-what-three-complex-cases-reveal
  11. Geographic atrophy: treatment decisions before foveal involvement. Ophthalmology Times. Published November 11, 2026. Accessed November 18, 2026. https://www.ophthalmologytimes.com/view/geographic-atrophy-treatment-decisions-before-foveal-involvement

Related to this article